This article is more than 5 years old. Information may no longer be current.

EuroPCR to highlight advancements in interventional cardiology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PARIS — Cardiology Today’s Intervention is onsite in Paris for the annual EuroPCR meeting, which will showcase the latest technological developments in the field of interventional cardiology, including renal denervation, transcatheter aortic valve replacement and left atrial appendage closure.

According to a press release issued by EuroPCR, more than 12,000 attendees are expected at the 4-day conference, which will take place from May 20 to May 23. The meeting will feature presentations of more than 700 scientific papers — 337 oral abstracts, 301 posters and 80 moderated posters — and 665 cases. The program also includes 34 oral presentations on innovations and 47 late-breaking clinical trials.

Currently slated in the late-breaking trials and innovations session include presentations on:

• The OCTAVIA study: mechanisms of atherothrombosis and vascular response to primary PCI in women vs. men with acute MI;
• 30-day outcomes from the SAPIEN 3 trial;
• The PRAGUE-16 pilot study: direct catheter-based thrombectomy in acute ischemic stroke;
• Transcatheter mitral valve implantation: first-in-man experience with the Fortis valve.

Also on tap are presentations examining renal denervation responders vs. nonresponders in the Global SYMPLICITY Registry; safety and 6-month durability of angioplasty in patients with erectile dysfunction; 2-year outcomes after left atrial appendage closure with the Amplatzer cardiac plug in patients with nonvalvular atrial fibrillation; patterns of use and clinical utility with fractional flow reserve; and much more.

Stay tuned to Cardiology Today’s Intervention and Healio.com/Intervention throughout the week for coverage of these and other exciting data from the meeting.